Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159807 · ClinicalTrials.gov registry record · NA
Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects
A NA study, sponsored by St. Luke's-Roosevelt Hospital Center.
- Completed
- Registry status
- NA
- Development phase
- 170
- Enrollment target
NCT02159807 is a NA study that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 170 participants.
The verdict
NCT02159807, a NA study, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what dose of medication administered through a combined spinal epidural (CSE) provides the optimal pain relief with the minimal amount of side effects. The 3 doses studied here (1.25, 1.66 and 2.5mg) are routinely use on the labor floor (depending on the physician preference) but the idea is to quantify safety, efficacy and side effects for each of these doses.
Interventions
- DRUG Bupivacaine
- DRUG Fentanyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2015-04-24 |
| Est. Completion | 2017-12-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159807
The ClinicalTrials.gov registry entry for NCT02159807 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's-Roosevelt Hospital Center, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT02159807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02159807 about?
NCT02159807 is a clinical study titled "Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects". The purpose of this study is to determine what dose of medication administered through a combined spinal epidural (CSE) provides the optimal pain relief with the minimal amount of side effects. The 3 doses studied here (1.25, 1.66 and 2.5mg) are routinely use on the labor floor (depending on the phy...
What is the current status of trial NCT02159807?
This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2015-04-24. Estimated completion is 2017-12-29.
What interventions are being tested in trial NCT02159807?
The interventions under investigation include: Bupivacaine (DRUG), Fentanyl (DRUG).
Who is sponsoring clinical trial NCT02159807?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.